Polaris Group (TPE:6550)
Taiwan
· Delayed Price · Currency is TWD 17.90
+0.40 (2.29%)
Apr 29, 2026, 1:30 PM CST
Polaris Group Revenue
In the year 2025, Polaris Group had annual revenue of 40.60M TWD, down -62.05%. Polaris Group had revenue of 6.02M in the quarter ending December 31, 2025, a decrease of -83.40%.
Revenue
40.60M
Revenue Growth
-62.05%
P/S Ratio
370.63
Revenue / Employee
246.07K
Employees
165
Market Cap
15.05B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 40.60M | -66.40M | -62.05% |
| Dec 31, 2024 | 107.00M | 99.52M | 1,330.29% |
| Dec 31, 2023 | 7.48M | 1.04M | 16.18% |
| Dec 31, 2022 | 6.44M | -8.60M | -57.19% |
| Dec 31, 2021 | 15.04M | 5.63M | 59.84% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Medigen Vaccine Biologics | 613.17M |
| EirGenix | 1.01B |
| AP Biosciences | 32.25M |
| TaiMed Biologics | 611.35M |
| Locus Cell | 12.74M |
| Ever Supreme Bio Technology | 1.02B |
| Lumosa Therapeutics | 35.83M |
| Tanvex BioPharma | 400.97M |